Annals of Coloproctology

Display

Sort by :

Original Articles

Impact of Adjuvant Therapy Type on Survival in Stage II/III Rectal Cancer Without Preoperative Chemoradiation: A Korean Multicenter Retrospective Study: Byung Mo Kang, Jeong-Heum Baek, Sun Jin Park, Seong Kyu Baek, Ki-Jae Park, Hong-Jo Choi, Byung-Noe Bae, Sun Keun Choi, Kap Tae Kim, Jin-Su Kim, Suk-Hwan Lee; Ann Coloproctol. 2018;34(3):144-151. Published online June 30, 2018; DOI: https://doi.org/10.3393/ac.2017.09.26.1

6,590 View
107 Download
4 Web of Science
4 Citations

Purpose
This study compared the oncologic impact of postoperative chemotherapy and chemoradiotherapy on patients with rectal cancer without preoperative chemoradiation.
Methods
This retrospective study analyzed 713 patients with a mean follow-up of 58 months who had undergone radical resection for stage II/III rectal cancer without preoperative treatment in nine hospitals from January 2004 to December 2009. The study population was categorized a chemotherapy group (CG, n = 460) and a chemoradiotherapy group (CRG, n = 253). Five-year overall survival (OS) and disease-free survival (DFS) were analyzed, and independent factors predicting survival were identified.
Results
The patients in the CRG were significantly younger (P < 0.001) and had greater incidences of low rectal cancer (P < 0.001) and stage III disease (P < 0.001). Five-year OS (P = 0.024) and DFS (P = 0.012) were significantly higher in the CG for stage II disease; however, they were not significantly different for stage III disease. In the multivariate analysis, independent predictive factors were male sex, low rectal cancer and stage III disease for OS and male sex, abdominoperineal resection, stage III disease and tumor-positive circumferential margin for DFS. However, adjuvant therapy type did not independently affect OS (hazard ratio [HR], 1.243; 95% confidence interval [CI], 0.794–1.945; P = 0.341) and DFS (HR, 1.091; 95% CI, 0.810–1.470; P = 0.566).
Conclusion
Adjuvant therapy type did not affect survival of stage II/III rectal cancer patients without neoadjuvant chemoradiotherapy. These results suggest that adjuvant therapy can be chosen based on the patient’s condition and the policies of the surgeons and hospital facilities.

Citations

Citations to this article as recorded by

Efficacies of radiotherapy in rectal cancer patients treated with total mesorectal excision or other types of surgery: an updated meta-analysis
Wenshu Wang, Runyuan Zhao, Xi Liang, Manjun Liu, Haiyan Bai, Jianli Ge, Binxi Yao, Zheng Zhi, Jianming He
Oncology Reviews.2025;[Epub] CrossRef
Management and Outcomes of Pathologic Upstaging of Clinical Stage I Rectal Cancers: An Exploratory Analysis
Alisha Lussiez, Samantha J. Rivard, Kamren Hollingsworth, Sherif R.Z. Abdel-Misih, Philip S. Bauer, Katherine A. Hrebinko, Glen C. Balch, Lillias H. Maguire
Diseases of the Colon & Rectum.2023; 66(4): 543. CrossRef
The oncological outcomes of postoperative radiotherapy in patients with stage II and III upper rectal cancer
Ilknur ALSAN CETIN, Sıtkı Utku AKAY
Marmara Medical Journal.2022;[Epub] CrossRef
Selection of Adjuvant Treatment Without Neoadjuvant Chemoradiotherapy for Patients With Rectal Cancer: Room for Further Investigation
In Ja Park
Annals of Coloproctology.2018; 34(3): 109. CrossRef

Intestinal Anastomosis by Use of a Memory-shaped Compression Anastomosis Clip (Hand CAC 30): Early Clinical Experience: Hak-Youn Lee, Jin-Hee Woo, Si-Young Park, Nam-Wook Kang, Ki-Jae Park, Hong-Jo Choi; J Korean Soc Coloproctol. 2012;28(2):83-88. Published online April 30, 2012; DOI: https://doi.org/10.3393/jksc.2012.28.2.83

6,043 View
36 Download
8 Citations

Abstract PDF

Purpose

The safety and the efficacy of the compression anastomosis clip (Hand CAC 30) have been demonstrated by animal studies. This study was designed to evaluate the clinical validity of the Hand CAC 30 in enterocolic side-to-side anastomosis after colonic or enteric resections.

Methods

A non-randomized prospective data collection was performed for patients undergoing a side-to-side anastomosis using the Hand CAC 30. Eligibility criteria for the use of the Hand CAC 30 were for anastomoses between the colon and the ileum or between two small bowels. The primary short-term endpoint was the rate of anastomotic leakage. Other clinical outcomes, including intra- and postoperative complications, length of operation time and hospital stay, and the clip elimination time were recorded.

Results

A total of 63 patients (male, 36) underwent an enteric or right-sided colonic resection followed by a side-to-side anastomosis using the Hand CAC 30. Laparoscopic surgery was performed in 36 patients, in whom one patient who underwent a laparoscopic right hemicolectomy was converted to an open procedure (1/32, 3.1%). One patient with ascending colon cancer showed postoperative anastomotic leakage and died of co-morbid ischemic heart disease. There were no other surgical mortalities. The exact date of expulsion of the clip could not be recorded because most patients were not aware of clip elimination. No patients manifested clinical symptoms of anastomotic stricture.

Conclusion

Short-term evaluation of the Hand CAC 30 anastomosis in patients undergoing enterocolic surgery proved it to be a safe and efficacious alternative to the standard hand-sewn or stapling technique.

Citations

Citations to this article as recorded by

Comparative early histologic healing quality of magnetic versus stapled small bowel anastomosis
Ana Sofia Ore, Ashley Althoff, David R. Kull, Thomas J. Baldwin, Jeffrey L. Van Eps, Evangelos Messaris
Surgery.2023; 173(4): 1060. CrossRef
An Automatic Suturing Machine for Intestinal Anastomosis: Advantages Compared With Hand-Suturing Technique
Sanaz Mosafer Khoorjestan, Gholamreza Rouhi
Surgical Innovation.2019; 26(2): 209. CrossRef
Biodegradable anastomotic tube prepared from diblock copolymers of mPEG-b-PLA and mPEG-b-PLGA
Xiaodong Zhang, Zuoqian Yu, Feizhao Jiang, Lechi Ye, Jinlei Li, Xingzhao Ye, Chungen Xing
Journal of Macromolecular Science, Part A.2019; 56(7): 667. CrossRef
Anastomosis colorrectales por compresión utilizando el dispositivo NiTi
Quintín Héctor González-Contreras, Mónica de Jesús-Mosso, Jesús Alberto Bahena-Aponte, Omar Aldana-Martínez, Karen Pineda-Solís, Sari Narsil Mejia-Arcadia
Cirugía y Cirujanos.2016; 84(6): 482. CrossRef
Laparoscopic colonic anastomosis using a degradable stent in a porcine model
Liang Ma, Xiu-Jun Cai, Hai-Hong Wang, Yan-Lan Yu, Di-Yu Huang, Guang-Ju Ge, Hai-Yi Hu, Shi-Cheng Yu
World Journal of Gastroenterology.2016; 22(19): 4707. CrossRef
Colorectal anastomosis using a compression device
Quintín Héctor González-Contreras, Mónica de Jesús-Mosso, Jesús Alberto Bahena-Aponte, Omar Aldana-Martínez, Karen Pineda-Solís, Sari Narsil Mejia-Arcadia
Cirugía y Cirujanos (English Edition).2016; 84(6): 482. CrossRef
Long term results of the use of compression anastomosis clips (CAC) in gastrointestinal surgery – the first report
Katarzyna Kuśnierz, Paweł Lampe
Polish Journal of Surgery.2015;[Epub] CrossRef
A nickel–titanium memory-shape device for gastrojejunostomy: comparison of the compression anastomosis clip and a hand-sewn anastomosis
Katarzyna Kusnierz, Zdzislaw Lekston, Dmytro Zhavoronkov, Slawomir Mrowiec, Pawel Lampe
Journal of Surgical Research.2014; 187(1): 94. CrossRef

Review

Colorectal Cancer with Multiple Metastases: Is Palliative Surgery Needed?: Hong-Jo Choi, Jin Yong Shin; J Korean Soc Coloproctol. 2011;27(5):226-230. Published online October 31, 2011; DOI: https://doi.org/10.3393/jksc.2011.27.5.226

4,596 View
31 Download
1 Citations

Abstract PDF

In patients with symptomatic incurable metastatic colorectal cancer (mCRC), the goal of resection of the primary lesion is to palliate cancer-related morbidity, including obstruction, bleeding, or perforation. In patients with asymptomatic primary tumors and incurable metastatic disease, however, the necessity of primary tumor resection is less clear. Although several retrospective analyses suggest survival benefit in patients who undergo resection of the primary tumor, applying this older evidence to modern patients is out of date for several reasons. Modern chemotherapy regimens incorporating the novel cytotoxic agents oxaliplatin and irinotecan, as well as the target agents bevacizumab and cetuximab, have improved median survival from less than 1 year with the only available single-agent 5-fluorouracil until the mid-1990s to over 2 years. In addition to significant prolongation of overall survival, combinations of novel chemotherapeutic and target agents have allowed improved local and distant tumor control, decreasing the likelihood of local tumor-related complications requiring surgical resection. Resection of an asymptomatic primary tumor risks surgical complications and may postpone the administration of chemotherapy that may offer both systemic and local control. In conclusion, the morbidity and the mortality of unnecessary surgery or surgery that does not improve quality of life or survival in patients with mCRC of a limited life expectancy should be carefully evaluated. With the availability of effective combinations of chemotherapy and target agents, systemic therapy for the treatment of life-threatening metastases would be a preferable treatment strategy for unresectable asymptomatic patients with mCRC.

Citations

Citations to this article as recorded by

Palliative laparoscopic bowel resection in stage IV colorectal cancer patients with unresectable metastasis
Kwan Mo Yang, Seok-Byung Lim, Yong Sik Yoon, Chan Wook Kim, In Ja Park, Chang Sik Yu, Jin Cheon Kim
Korean Journal of Clinical Oncology.2013; 9(2): 134. CrossRef

Original Article

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer: Hyeong-Joon Jeon, Jin-Hee Woo, Hak-Yoon Lee, Ki-Jae Park, Hong-Jo Choi; J Korean Soc Coloproctol. 2011;27(3):140-146. Published online June 30, 2011; DOI: https://doi.org/10.3393/jksc.2011.27.3.140

11,196 View
58 Download
12 Citations

Abstract PDF

Purpose

Great progress has been made in the adjuvant treatment of colon cancer. The aim of this study was to evaluate the efficacy of postoperative adjuvant chemotherapy using the FOLFOX regimen in patients with stage III and high-risk stage II colon cancer.

Methods

Eighty-two patients who underwent a potentially curative resection for stage III or high-risk stage II colon cancer were enrolled in this retrospective study. They received FOLFOX4 or modified FOLFOX6. The primary endpoint was disease-free survival.

Results

During the median follow-up of 37 months (range, 21 to 61 months), 14 patients experienced disease relapse. The disease-free survival rate at 3 years was 82.9%: 84.6% for stage II and 82.6% for stage III. At the time of the analysis, 8 patients were dead from recurrence. The probability of overall survival at 5 years was 74.5%: 90% for stage II and 74.6% for stage III. Grade 3 or 4 hematologic adverse events included neutropenia (40.2%), anemia (2.4%), and thrombocytopenia (1.2%). Gastrointestinal toxicities included grade 3 or 4 nausea (4.9%) and stomatitis (2.4%). Peripheral sensory neuropathy was observed in 81.7% of the patients during treatment. Of the 11 patients (13.4%) who had grade 3 peripheral sensory neuropathy during treatment, grade 3 symptoms were persistent in 3 patients with gait disturbance at the time of analysis. No treatment-related deaths were recorded.

Conclusion

Postoperative chemotherapy using the FOLFOX regimen, oxaliplatin in combination with 5-fluorouracil and leucovorin, is effective and tolerable in patients with stage III and high-risk stage II colon cancer.

Citations

Citations to this article as recorded by

Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries
Bazarbashi Shouki, Alnajjar Abdelsalam, Al Sharm Abdullah, Alshammari Kanan, Al Sherhi Ahmed, Dawoud Emad, Heinemann Volker, Aseafan Mohamed, Chehal Aref, Alghamdi Mohammed, Hamza Dina, Khoury Maroun, Venniyoor Ajit, Mahrous Mervat, Rasul Kakil, Elsamany
Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef
Cathayanon E induces apoptosis and enhances oxaliplatin sensitivity in colorectal cancer through suppression of MCL1
Liang Cen, Xin Hu, Guozhen An, Lichao Wang, Yanghao Hu, Junjie He, Hanghang Qin, Yongsen Li, Hongjuan Cui
Apoptosis.2025;[Epub] CrossRef
Transcriptomic and Cytogenetic Analysis of Oxaliplatin-Resistant Colorectal Adenocarcinoma HCT116 Cells to Identify Markers Associated with Platinum Resistance
Alisa Morshneva, Olga Gnedina, Ksenia Fedotova, Natalija Yartseva, Nikolay Aksenov, Maria Igotti
International Journal of Molecular Sciences.2025; 26(18): 8869. CrossRef
Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
Shirin Kianersi, Sina Salari, Hamid Rezvani, Mohammad A. Araskhan, Alireza Shirangi, Mohammad R. Fathi, Mahmoud D. Ghorbi
Journal of Education and Health Promotion.2023;[Epub] CrossRef
Extending the boundaries of cancer therapeutic complexity with literature text mining
Danna Niezni, Hillel Taub-Tabib, Yuval Harris, Hagit Sason, Yakir Amrusi, Dana Meron-Azagury, Maytal Avrashami, Shaked Launer-Wachs, Jon Borchardt, M. Kusold, Aryeh Tiktinsky, Tom Hope, Yoav Goldberg, Yosi Shamay
Artificial Intelligence in Medicine.2023; 145: 102681. CrossRef
Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
T. Quang Nguyen, T. Oanh Bui, P. Thao Tran, V. Thuan Tran, V. Hieu Nguyen, Q. Hoan Chu, T. A. Tuyet Bui, N. Quynh Le, V. Quang Le, V. Tu Dao
Cancer Control.2019;[Epub] CrossRef
Operative Versus Nonoperative Management of Appendicitis: A Long-Term Cost Effectiveness Analysis
Lindsay A. Sceats, Seul Ku, Alanna Coughran, Britainy Barnes, Emily Grimm, Matthew Muffly, David A. Spain, Cindy Kin, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert
MDM Policy & Practice.2019;[Epub] CrossRef
Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer
Shelby N. Bess, Gage J. Greening, Timothy J. Muldoon
Cytokine & Growth Factor Reviews.2019; 49: 1. CrossRef
Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients
Akie Watanabe, Chang Cheng Yang, Winson Y. Cheung
Medical Oncology.2018;[Epub] CrossRef
Risk Stratification in Patients with Stage II Colon Cancer
Ramzi Amri, Jonathan England, Liliana G. Bordeianou, David L. Berger
Annals of Surgical Oncology.2016; 23(12): 3907. CrossRef
Anti-Colorectal Cancer Chemotherapy-Induced Diarrhoea: Current Treatments and Side-Effects
Rachel M. McQuade, Joel C. Bornstein, Kulmira Nurgali
International Journal of Clinical Medicine.2014; 05(07): 393. CrossRef
Multiple Cancers in a Patient with Systemic Sclerosis and Aggravated Interstitial Lung Disease by Chemotherapy
Chan Kwon Park, Seok Jong Lee, Hyung Jun Cho, Kyeong Soo Lee, Sung Jun Kim, Gu Min Cho, Ha Ni Lee
Tuberculosis and Respiratory Diseases.2013; 75(3): 111. CrossRef

First
Prev
Page of 1
Next
Last

Search